Key Insights

Highlights

Success Rate

83% trial completion

Published Results

15 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

7.4%

6 terminated out of 81 trials

Success Rate

82.9%

-3.6% vs benchmark

Late-Stage Pipeline

9%

7 trials in Phase 3/4

Results Transparency

52%

15 of 29 completed with results

Key Signals

15 with results83% success

Data Visualizations

Phase Distribution

57Total
Not Applicable (20)
Early P 1 (5)
P 1 (2)
P 2 (23)
P 3 (6)
P 4 (1)

Trial Status

Completed29
Unknown16
Recruiting13
Active Not Recruiting12
Terminated6
Withdrawn2

Trial Success Rate

82.9%

Benchmark: 86.5%

Based on 29 completed trials

Clinical Trials (81)

Showing 20 of 20 trials
NCT04245176Not ApplicableCompleted

Genetic Testing for All Breast Cancer Patients (GET FACTS)

NCT04414202Active Not RecruitingPrimary

Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis

NCT04677816Phase 2Recruiting

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

NCT03387553Early Phase 1Active Not Recruiting

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

NCT05318274Not ApplicableActive Not Recruiting

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

NCT03987555Suspended

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

NCT06268665Phase 2Recruiting

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT07421479Active Not RecruitingPrimary

Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)

NCT05383196Phase 1Active Not Recruiting

Onvansertib + Paclitaxel In TNBC

NCT05412225Phase 1Recruiting

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

NCT04368702Not ApplicableRecruiting

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04448886Phase 2Active Not RecruitingPrimary

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT06328465Not ApplicableRecruitingPrimary

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

NCT03344965Phase 2Active Not Recruiting

Olaparib In Metastatic Breast Cancer

NCT03212170Phase 2CompletedPrimary

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

NCT04074720Recruiting

Prospective Breast Cancer Biospecimen Collection

NCT07260188RecruitingPrimary

Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy

NCT04553770Phase 2Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT05607004Phase 2Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT04230109Phase 2RecruitingPrimary

Sacituzumab Govitecan In TNBC

Scroll to load more

Research Network

Activity Timeline